There is something quietly surreal about watching two of the most famous people on the planet swap messages on social media about reversing human aging — and then discovering that the conversation was pointing at something real. When Elon Musk, sitting in Davos, said aging is “very solvable” and likely has an explanation that will seem “obvious” in hindsight, most people probably filed it under billionaire optimism. But David Sinclair, the Harvard professor who has spent decades staking his reputation on the science of longevity, wasn’t speaking in abstractions when he replied.
Clinical trials, he confirmed, were beginning. And the drug they were discussing — coded ER-100 — had just received FDA clearance to be tested in human volunteers. That’s not a press release. That’s a turning point, or at least the closest thing to one the field has ever seen.
| Category | Details |
|---|---|
| Key Scientist | Prof. David A. Sinclair, Ph.D., A.O. |
| Institution | Harvard Medical School — Department of Genetics |
| Co-Director | Paul F. Glenn Center for Biology of Aging Research |
| Company | Life Biosciences (Boston, MA) |
| Co-Founded By | David Sinclair |
| Drug Code Name | ER-100 |
| Trial Phase | Phase 3 (FDA Approved to Proceed) |
| Initial Target Condition | Glaucoma (optic nerve damage) |
| Technique | Epigenetic Reprogramming (Yamanaka Factors) |
| Phase 2 Published | July 12, 2023 — Aging Journal |
| Key Discovery | Six chemical cocktails that restore youthful cell states in under one week |
| Trial Method | Viral injection of three reprogramming genes into the eye, activated by low-dose doxycycline |
| Nobel Prize Basis | Prof. Shinya Yamanaka, 2012 — discovery of transcription factors resetting cell age |
| Reference Website | Harvard Medical School — Sinclair Lab |
Life Biosciences, the small Boston startup that Sinclair cofounded, is now moving forward with what may be the most consequential medical experiment of this generation. The plan, at its core, is to inject viruses carrying three powerful reprogramming genes into the eyes of roughly a dozen glaucoma patients.
Patients take a low dose of the antibiotic doxycycline, which acts as a kind of switch — turning the genes on while the drug is in the system, then off when it isn’t. The idea is to coax the damaged cells of the optic nerve back into something resembling their younger, healthier selves. It’s controlled. It’s careful. It’s also, depending on your frame of reference, absolutely wild.
The science underneath it traces back to a Nobel Prize. In 2006, Japanese scientist Shinya Yamanaka discovered that introducing just four genes into an adult cell could essentially convince it to forget everything it had learned about being old.
These genes — now called Yamanaka factors — reset cells to a stem-cell state, effectively erasing the biological markers of age. The implications were staggering and also terrifying, because unchecked reprogramming in living animals tends to produce tumors. The cells reset too completely. They lose track of what they’re supposed to be.
What Sinclair’s team spent years trying to solve is whether you can use a partial version of that reset — enough to reverse the damage of aging, not so much that cells lose their identity entirely. The results from their earlier work were striking. Mice regained vision.
Monkeys, more recently, showed similar improvements. Then, in July 2023, a research paper published in the journal Aging by a team spanning Harvard, MIT, and the University of Maine added something new: a chemical approach that achieved similar results without gene therapy at all. Six chemical cocktails, the researchers found, could restore cells to a youthful transcriptomic profile in under a week. The door to a pill — an actual pill — opened a crack.
It’s still very early, and anyone who has followed biomedical research long enough knows that what works in mice has a way of disappointing in people. There’s a sense in the field, though, that this time something is different — not because the hype is louder, but because the underlying mechanism is more fundamental. Reprogramming isn’t targeting one protein or blocking one pathway.
It’s attempting to reset the operating system. Karl Pfleger, an investor backing a smaller UK startup in the same space, put it plainly: “Reprogramming is like the AI of the bio world. It’s the thing everyone is funding.”
That funding is real and growing. Altos Labs, New Limit, Retro Biosciences — firms backed by some of the biggest names in tech have collectively poured hundreds of millions into this idea. The financial conviction is notable, though it’s still unclear whether that money reflects genuine scientific confidence or the particular obsessions of very wealthy men who would prefer not to die. Probably some of both.
What is clear is that Life Biosciences is now in territory no company has entered before. Michael Ringel, the company’s chief operating officer, said at an industry event last fall that this trial represents “the first time in human history, in the millennia of human history, of looking for something that rejuvenates.” That’s a large claim. It’s also, given what has been published and peer-reviewed, not an unreasonable one.
Sinclair himself has been direct about where things stand. “Until recently, the best we could do was slow aging,” he said when the chemical reprogramming results were published. “New discoveries suggest we can now reverse it.”
He envisions a future where a single pill might restore eyesight, repair aging tissue, and treat a range of conditions that currently have no meaningful cure. That future is still speculative. But the Phase 3 trial is not speculation. It is happening, in a clinic, with real patients, now.
It’s hard not to feel something watching this unfold — a mix of genuine wonder and cautious disbelief, the kind that comes from knowing how many times promising biology has stalled between a journal paper and an actual treatment. The biology here is sound. The question is always translation.
Whether ER-100 will work in humans the way it worked in animals, whether the safety profile holds, whether the vision patients regain is meaningful and lasting — none of that is known yet. What is known is that the starting bell Ringel promised has finally rung, and the race it signals may be unlike anything medicine has attempted before.